Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
Quantum BioPharma (NASDAQ: QNTM) has successfully closed the final tranche of its previously announced financing, raising $2.42 million in Debenture Units. This completion brings the total financing to $5 million, following amendments made on January 20, 2025, and improved terms announced on March 7, 2025.
The funds will be allocated to advance research and development of drug candidates, commercialization efforts, and general working capital. The company projects these funds will sustain operations until at least Q1 2027. Additionally, Quantum has initiated the development of rekvry™, a new alcohol misuse treatment designed for emergency and hospital settings, aimed at reducing healthcare costs and resource burden.
Quantum BioPharma (NASDAQ: QNTM) ha chiuso con successo l'ultima tranche del finanziamento precedentemente annunciato, raccogliendo 2,42 milioni di dollari in Unità di Obbligazione. Questa conclusione porta il finanziamento totale a 5 milioni di dollari, dopo le modifiche apportate il 20 gennaio 2025 e i termini migliorati annunciati il 7 marzo 2025.
I fondi saranno destinati a promuovere la ricerca e lo sviluppo di candidati farmaceutici, sforzi di commercializzazione e capitale circolante generale. L'azienda prevede che questi fondi sosterranno le operazioni fino almeno al primo trimestre del 2027. Inoltre, Quantum ha avviato lo sviluppo di rekvry™, un nuovo trattamento per l'abuso di alcol progettato per situazioni di emergenza e ambienti ospedalieri, mirato a ridurre i costi sanitari e il carico sulle risorse.
Quantum BioPharma (NASDAQ: QNTM) ha cerrado con éxito la última tranche de su financiamiento previamente anunciado, recaudando 2.42 millones de dólares en Unidades de Debentures. Esta finalización lleva el financiamiento total a 5 millones de dólares, tras las enmiendas realizadas el 20 de enero de 2025 y los términos mejorados anunciados el 7 de marzo de 2025.
Los fondos se destinarán a avanzar en la investigación y el desarrollo de candidatos a medicamentos, esfuerzos de comercialización y capital de trabajo general. La empresa proyecta que estos fondos sostendrán las operaciones hasta al menos el primer trimestre de 2027. Además, Quantum ha iniciado el desarrollo de rekvry™, un nuevo tratamiento para el abuso de alcohol diseñado para situaciones de emergencia y entornos hospitalarios, con el objetivo de reducir los costos de atención médica y la carga de recursos.
Quantum BioPharma (NASDAQ: QNTM)는 이전에 발표된 자금 조달의 마지막 분할을 성공적으로 마감하고 242만 달러를 채권 단위로 모금했습니다. 이 완료로 총 자금 조달액은 500만 달러에 이르며, 2025년 1월 20일에 수정된 사항과 2025년 3월 7일에 발표된 개선된 조건을 반영합니다.
이 자금은 의약품 후보의 연구 및 개발, 상업화 노력 및 일반 운영 자본을 지원하는 데 사용됩니다. 회사는 이 자금이 최소한 2027년 1분기까지 운영을 지속할 것이라고 예상하고 있습니다. 또한, Quantum은 긴급 상황 및 병원 환경을 위해 설계된 알코올 남용 치료제 rekvry™의 개발을 시작했습니다. 이는 의료 비용과 자원 부담을 줄이는 것을 목표로 하고 있습니다.
Quantum BioPharma (NASDAQ: QNTM) a réussi à clôturer la dernière tranche de son financement précédemment annoncé, levant 2,42 millions de dollars en unités de débenture. Cette finalisation porte le financement total à 5 millions de dollars, suite aux modifications apportées le 20 janvier 2025 et aux conditions améliorées annoncées le 7 mars 2025.
Les fonds seront alloués à l'avancement de la recherche et du développement de candidats médicaments, aux efforts de commercialisation et au capital de travail général. L'entreprise prévoit que ces fonds permettront de soutenir les opérations jusqu'au moins le premier trimestre 2027. De plus, Quantum a lancé le développement de rekvry™, un nouveau traitement pour l'abus d'alcool conçu pour les situations d'urgence et les environnements hospitaliers, visant à réduire les coûts de santé et la charge sur les ressources.
Quantum BioPharma (NASDAQ: QNTM) hat erfolgreich die letzte Tranche seiner zuvor angekündigten Finanzierung abgeschlossen und 2,42 Millionen Dollar in Anleiheneinheiten gesammelt. Dieser Abschluss bringt die Gesamtfinanzierung auf 5 Millionen Dollar, nach den Änderungen, die am 20. Januar 2025 vorgenommen wurden, und den verbesserten Bedingungen, die am 7. März 2025 bekannt gegeben wurden.
Die Mittel werden verwendet, um die Forschung und Entwicklung von Arzneimittelkandidaten, Vermarktungsbemühungen und allgemeines Betriebskapital voranzutreiben. Das Unternehmen prognostiziert, dass diese Mittel die Operationen bis mindestens zum ersten Quartal 2027 unterstützen werden. Darüber hinaus hat Quantum die Entwicklung von rekvry™ initiiert, einer neuen Behandlung für Alkoholmissbrauch, die für Notfälle und Krankenhausumgebungen konzipiert ist und darauf abzielt, die Gesundheitskosten und die Belastung der Ressourcen zu reduzieren.
- Secured total financing of $5 million with improved terms
- Extended cash runway until Q1 2027
- Initiated development of new product rekvry™ for alcohol misuse treatment
- Reliance on debenture financing may increase debt burden
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”) is pleased to announce that it has closed the final tranche (“Final Tranche”) of the offering announced on December 5, 2024 (the “December 5 NR”) as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the “March 7 NR”). The Company issued 2,420 Debenture Units (as defined in the December 5 NR, as amended by the March 7 NR) for
In addition, the Company has begun development of a formulation for rekvry™ – an alcohol misuse treatment for emergency and hospital settings. The Company believes that rekvry™ fulfills an unmet need in healthcare settings, reducing the costs and burden on healthcare resources and staff.
All amounts in this press release are expressed in CAD.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
